Senior Counsels Jason Drori and Simon Elliott contributed an article to IPPro Patents, “The PRICED Act: A Bold Attempt to Change the Biologics Market,” on August 17, 2016. The article examined the Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act proposed legislation that aims to reduce the market exclusivity period for new biologics from 12 to seven years in the United States. Drori and Elliott discussed how the PRICED Act may be a more direct threat to the biologics industry and risks upsetting a delicate balance.
Related Insights
December 19, 2025
Health Care Law Today
Gender Affirming Care for Minors: CMS and HHS Propose Limits on “Sex Rejection Procedures” and Expanded Enforcement Pathways
On December 18, 2025, the U.S. Department of Health and Human Services (HHS) held a press conference focused on what is defined as “sex…
December 19, 2025
Foley Viewpoints
Prohibition to Prescription: What Trump’s Marijuana Executive Order Really Means
On December 18, 2025, President Donald Trump issued an Executive Order, Increasing Medical Marijuana and Cannabidiol Research, that…
December 18, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…